CHADDS FORD, Pa.-- Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. (Nasdaq: ENDP), today announced that, according to the latest IMS data estimates, the reformulated OPANA ER (oxymorphone HCl) incorporating Grunenthal's INTAC Technology designed to be crush-resistant accounts for more than 90 percent of the OPANA ER total prescription volume.
"Patient safety, including appropriate use of our products, remains one of Endo's top priorities, and we are proud to announce that almost all remaining inventory of the original formulation of OPANA ER has been utilized," stated Julie McHugh, Chief Operating Officer for Endo Health Solutions. "We are passionate about the benefits of our reformulated product and hope to collaborate with the FDA to make crush-resistant formulations of long acting opioids the new standard of entry to the market."
With the intent of helping drive appropriate use of OPANA ER, Endo ceased production of the original formulation and began manufacturing only the version employing INTAC Technology in February 2012.
Additionally, Endo recently submitted two Citizen Petitions (CP) encouraging the U.S. Food and Drug Administration (FDA) to partner with the company in an effort to employ standards that will better manage patient access to vital pain management medications like OPANA ER while also helping drive appropriate use of the products.
PR Newswire